Hospital Universitario San Juan De Alicante — Clinical Trial Site

20 Registered trials

6 Currently recruiting

Organisation

Hospital Universitario San Juan De Alicante

Location

Sant Joan D'alacant, Spain

Identifier

ORG-100042445

Address

Carretera N-332 Alicante-Valencia S/n, 03550, Spain

Departments

#6650:Servicio pediatría
Allergology
Allergy
Anestesiología y Reanimación
Cardiology
Cardiology Service
Endocrinología
Hematology Department
Medical Oncology
Oncology
Oncology Service
reumatologia

Clinical trials at this site (20)

Search interface

Randomized clinical trial to assess the efficacy and safety of a strategy for primary prevention of cardiovascular disease in patients with … Pending

2025-521086-28-00 CHRONIC INFLAMMATORY RHEUMATIC DISEASE: rheumatoid arth 6
Clinical trial to assess the efficacy and safety of a vaccine for dust mite and Lepidoglyphus destructor allergy. Pending

2025-522771-28-00 Aetiological treatment of moderate-to-severe allergic r 5
Phase III clinical trial to evaluate the efficacy and safety of specific immunotherapy with mannanconjugated allergoids for the treatment of… Recruiting

2023-508547-51-00 Aetiological treatment of moderate-to-severe allergic r 5 2025-11-18
Study to evaluate efficacy and safety of inclisiran in children aged 2 to under 12 years of age with homozygous familial hypercholesterolemi… Recruiting

2024-514595-41-00 homozygous familial hypercholesterolemia 5 2025-08-05
A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec… Recruiting

2024-512926-27-00 patients with estrogen receptor-positive/human epiderma 5 2024-12-12
A PHASE 2 STUDY TO RESEARCH THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6I PLUS ENDOCRINE THERAPY IN ADVANCED BREAST CANCE… Recruiting

2024-512360-55-00 Unresectable locally recurrent or metastatic hormone re 4 2025-06-30
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
An international investigator initiated trial to capture different approaches in the treatment of Haemophilia A Patients With FVIII Inhibito… Recruiting

2024-516741-39-00 Haemophilia A 6 2020-01-14
Phase II Study of Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-Low Breast Cancer Patients Presenting with Newly Diagnosed or Progressing… Ended

2023-506702-39-00 HER2-low breast cancer presenting with newly diagnosed 4 2024-06-05
Randomized clinical trial assessing the value of Beta-Blockers and Antiplatelet Agents in patients with Spontaneous Coronary Artery Dissecti… Ended

2024-516039-28-00 Spontaneous Coronary Artery Dissection. 6 2021-09-28
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 HR+/HER2- early breast cancer 5 2020-07-23
Phase II trial of trastuzumab deruxtecan in first-line treatment HER2-positive locally advanced or metastatic breast cancer (MBC) patients c… Ended

2023-503627-26-00 Metastatic breast cancer 4 2023-09-28
Single arm phase II study of the efficacy and safety of the combination of Trastuzumab plus TUCAtinib plus viNorelbine in patients with HER2… Ended

2024-512590-27-00 Non-resectable locally advanced or metastatic HER2-posi 9 2023-03-08
Study to evaluate the efficacy and safety of switching to insulin glargine 300 U/ml from insulin glargine 100 U/ml in patients with type 2 d… Ended

2024-518403-22-00 Diabetes mellitus II 6 2022-06-20
Clinical trial developed at various hospitals where each patient randomly receive in parallel groups either placebo or treatment. Nor patien… Ended

2024-519527-14-00 Allergic rhinoconjunctivitis 5 2022-06-09
Hemodynamic Phenotype-Based,Capillary Refill Time-Targeted Resuscitation In Early Septic Shock:ANDROMEDA-SHOCK-2 Ended

2024-519691-10-00 Septic Shock 6 2022-05-27
A Phase 3, randomized, double-blind, placebo-controlled, multicenter study of IV FDY-5301 in patients with a myocardial infarction (STEMI) Ended

2024-514372-40-00 Anterior ST-Elevation Myocardial Infarction 5 2022-04-12
A clinical trial with nadunolimab in combination with gemcitabine plus carboplatin in patients with advanced triple negative breast cancer. … Ended

2024-512052-38-00 Advanced triple negative breast cancer 9 2021-12-02
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negati… Ended

2023-508472-11-00 Patients with early breast cancer 5 2018-06-13